Diabetic Nephropathy Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Diabetic Nephropathy Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

The global Diabetic Nephropathy market is set for robust growth over the next decade. According to recent market analysis, the market is expected to expand at a compound annual growth rate (CAGR) of 4.7%, reaching a valuation of around $3.6 billion by 2031. In 2024, the market is projected to achieve a revenue of $2.6 billion, highlighting a steady upward trajectory driven by advancements in research and development and the rising prevalence of diabetes.

Historical Sales Analysis and Future Market Outlook

From 2017 to 2022, the global Diabetic Nephropathy market demonstrated a significant period of growth. Moving forward, the market is anticipated to continue its expansion, underscored by the increasing incidence of both type 1 and type 2 diabetes. Diabetic nephropathy, also known as diabetic kidney disease, poses a substantial challenge to kidney function, emphasizing the need for effective treatments and management strategies.

Key Drivers of Market Growth

Several factors are contributing to the growth of the Diabetic Nephropathy market:

1. Increasing Prevalence of Diabetes: The rising number of diabetic patients globally is a primary driver. According to the International Diabetes Federation, diabetes affected 537 million people in 2021, with projections estimating this number will reach 643 million by 2030.

2. Advancements in Research and Development: Ongoing research efforts are pivotal in developing new treatments. ClinicalTrials.gov reported over 50 ongoing studies related to diabetic nephropathy treatment in 2021, underscoring the focus on this area.

3. Introduction of New Medications: The approval of new drugs, such as the FDA-approved SGLT2 inhibitor canagliflozin (Invokana) in 2019, is enhancing treatment options and outcomes for diabetic nephropathy patients.

4. Increased Awareness and Diagnostic Rates: Enhanced awareness and diagnostic rates of chronic kidney disease (CKD) and diabetic nephropathy are driving market growth, especially in developed countries like the United States.

Challenges Impacting Market Growth

Despite the positive outlook, the Diabetic Nephropathy market faces several challenges:

1. High Cost of Treatment: The financial burden associated with diabetic nephropathy treatment is significant. Patients with diabetic kidney disease (DKD) incur higher medical costs compared to those without complications.

2. Lack of Comprehensive Treatment: Currently, no complete cure exists for diabetic nephropathy. Available medications primarily aim to control or delay disease progression.

3. Inadequate Healthcare Infrastructure: In low-income countries, inadequate planning for diabetic nephropathy treatment and a lack of trained specialists hinder market growth.

Regional Market Insights

1. United States: Accounting for approximately 33.7% of the global market share, the United States remains a dominant player. The high prevalence of chronic kidney disease (CKD) and well-established healthcare infrastructure contribute to the country's market strength.

2. United Kingdom: With a 5.4% market share, the UK benefits from developed guidelines for diabetic nephropathy treatment, emphasizing individualized care and accurate blood pressure management.

3. Germany: Holding about 6.4% of the market, Germany shows significant potential due to high rates of undiagnosed early CKD and an increasing focus on early diagnosis and tailored treatments.

4. China: With a 4.2% market share, China is expected to see growth driven by government initiatives like the Healthy China Initiative (2019-2030), aimed at raising awareness and improving diabetes management.

Category-wise Market Insights

1. Drug Class: Angiotensin receptor blockers (ARBs) accounted for 42.3% of the total market share. These medications are effective in slowing the progression of diabetic nephropathy and reducing proteinuria in type 2 diabetes patients.

2. Diabetes Type: Type-II diabetes, which constituted around 76.5% of the market share, is a major focus area due to its high prevalence and association with end-stage kidney disease (ESKD).

3. Route of Administration: The oral route of administration held about 62.3% of the market share, favored for its non-invasiveness, patient compliance, and convenience.

4. Distribution Channel: Hospital pharmacies dominated the market with a 63.1% share, driven by the growing number of hospital visits for diagnosis and treatment of diabetic nephropathy.

Competitive Landscape

Key players in the Diabetic Nephropathy market are investing heavily in research and development to introduce innovative treatments. Strategic alliances, mergers, and acquisitions are common as companies aim to expand their market presence. Notable developments include:
• The joint announcement by Boehringer Ingelheim and Eli Lilly and Company regarding the FDA approval of empagliflozin (Jardiance) tablets in January 2023 for reducing cardiovascular death and kidney disease progression in CKD patients.
• Bayer's introduction of finerenone in India in August 2022 as a treatment for type-2 diabetes and chronic kidney disease (CKD).

As the global burden of diabetes continues to rise, the demand for effective diabetic nephropathy treatments will grow. The market is well-positioned for significant advancements, offering new hope for patients and healthcare providers worldwide.

Key Market Players Include
• AstraZeneca (UK.)
• Pfizer Inc (US.)
• Allergan, Inc (Ireland)
• Bristol-Myers Squibb Company (US.)
• Endo International plc (Ireland)
• Dr. Reddy's Laboratories Ltd (India)
• Sun Pharmaceutical Industries Ltd (India)
• Teva Pharmaceutical Industries Ltd (Israel)
• Novartis AG (Switzerland)
• Eli Lilly and Company (India)
• Mylan NV (US.)
• Cipla Inc (India)
• Lupin (India)
• Aurobindo Pharma (India)
• Sanofi (France)
• Fresenius SE & Co. KGaA (Germany)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Takeda Pharmaceutical Company Limited (Japan)
• Abbott (US.)

Global Diabetic Nephropathy market is Segmented as Below:

By Drug Class:
• Diuretics
• Angiotensin Receptor Blockers
• Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
• Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors
• Others

By Diabetes Type:
• Type-1 Diabetes
• Type-2 Diabetes

By Route of Administration:
• Oral
• Parenteral
• Others

By Distribution Channel:
• Hospitals Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

By Region:
• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East and Africa

Please note: The PDF e-mail from publisher version of this report is for a global site license. Delivery Timelines - 5 working days.